Halozyme Therapeutics (HALO) SVP Michael J. Labarre Sells 10,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, July 24th.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $55.12, for a total value of $551,200.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $9,269,861.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $55.15 on Thursday. The company has a 50-day simple moving average of $49.62 and a two-hundred day simple moving average of $42.35. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $56.50. The firm has a market capitalization of $7.02 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 0.56 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Read Our Latest Report on Halozyme Therapeutics